An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

SMI-PH-202 is an open-label extension (OLE) study evaluating the long-term impact of treprostinil SMI on safety, tolerability, and efficacy by providing it to PH-COPD patients who participated in a preceding Phase 2 or 3 study. Eligible participants will be enrolled and initiate open-label treprostinil SMI in a single arm; there is inherently no control or comparator arm. Participants will return for in-clinic visits at Weeks 4 and 12 and every 12 weeks thereafter. Treatment with treprostinil SMI will continue until the participant either prematurely discontinues treatment, marketing approval of treprostinil SMI for PH-COPD is granted, or the study is discontinued by the Sponsor. Participants may remain in the study for up to 7.5 years.